Wallerian degeneration of physically injured axons involves a well-defined molecular 27 pathway linking loss of axonal survival factor NMNAT2 to activation of pro-28 degenerative protein SARM1. Manipulating the pathway through these proteins led to 29 the identification of non-axotomy insults causing axon degeneration by a Wallerian-30 like mechanism, including several involving mitochondrial impairment. Mitochondrial 31 dysfunction is heavily implicated in Parkinson's disease, Charcot-Marie-Tooth 32 disease, hereditary spastic paraplegia and other axonal disorders. However, whether 33 and how mitochondrial impairment activates Wallerian degeneration has remained 34 unclear. Here, we show that disruption of mitochondrial membrane potential leads to 35 axonal NMNAT2 depletion in mouse sympathetic neurons, increasing the substrate-36
INTRODUCTION 46
Studies of axon degeneration following axotomy (Wallerian degeneration) and of the axon-protective protein WLD S have led to the discovery of critical endogenous 48 regulators of the mechanisms resulting in axon degeneration (Conforti et al., 2014; 49 Gerdts et al., 2016 ). The current model predicts that the pathway regulating Wallerian 50 degeneration (Wallerian pathway) is activated by the loss in the axon of the labile 51 nicotinamide mononucleotide adenylyl-transferase 2 (NMNAT2), a nicotinamide 52 adenine dinucleotide (NAD)-synthesising enzyme. Axonal NMNAT2 levels decline 53 within a few hours when its transport and/or synthesis are impaired (Gilley and Most studies on the Wallerian pathway have used a physical injury model, but there is 65 clear evidence that related degenerative mechanisms can be activated by many non-66 injury stresses (Conforti et al., 2014) . However, the vast majority of non-axotomy 67 models were performed when a more comprehensive understanding of the Wallerian 68 pathway was lacking and were mostly identified as being Wallerian-like by targeting 69 just a single step in the pathway (either by expressing of WLD S /NMNATs or, more 70 recently, by Sarm1 deletion). Both WLD s and SARM1 have the potential to influence 71 other cellular mechanisms, such as nuclear NAD synthesis and innate immunity, 72 respectively, so involvement of the Wallerian pathway is best supported by multiple 73 lines of evidence. 74
The link between mitochondria and the Wallerian pathway is particularly intriguing. 75
Mitochondrial dysfunction is a common theme in a wide group of neurodegenerative 76 disorders in which axon degeneration is central, including Parkinson's disease (PD), 77
Charcot-Marie-Tooth disease, hereditary spastic paraplegia and Friedrich's ataxia 78 (Court and Coleman, 2012) . We and others have previously shown that mitochondria 79 contribute to the later stages of Wallerian degeneration, where the axotomy itself 80 activates the Wallerian pathway (Barrientos et al., 2011; Loreto et al., 2015) . However, 81 mitochondrial depolarisation, caused by the mitochondrial uncoupler Carbonyl 82 cyanide m-chlorophenyl hydrazone (CCCP), also leads to degeneration of uninjured 83 axons , which is rescued by Sarm1 deletion (Summers et al., 84 2014) . Additional studies, both in vitro and in vivo, link the Wallerian pathway to 85 mitochondrial impairment. Wld S mice are protected against nigrostriatal axon 86 degeneration after intraperitoneal administration of the mitochondrial complex-1 87 inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Hasbani and O'Malley, 88 2006 Here we combine multiple lines of evidence to firmly establish a role for the Wallerian 96 pathway in axon degeneration caused by mitochondrial depolarisation in the absence 97 of a physical injury. We also corroborate these findings using an in vivo genetic model 98 of mitochondrial dysfunction, reporting a neuroprotective role of regulators of Wallerian 99 degeneration in dopaminergic neuron loss in Pink1 mutant flies. 100 Loreto et al., 2015; Walker et al., 2017) . We therefore tested whether CCCP treatment 126 led to NMNAT2 depletion in neurites (which were uninjured until immediately prior to 127 harvesting separately from their cell bodies) and found that levels of this protein in 128 neurites rapidly decline from 2 hr after CCCP addition ( Fig. 2A,B ). Loss of NMNAT2 129 occurred before any visible morphological damage to neurites (Fig. 2C ), also 130 confirmed by the absence of changes to b-actin levels ( Fig. 2A ). Levels of SCG10, 131 another short-lived protein comigrating with NMNAT2 (Milde et al., 2013) and involved 132 in Wallerian degeneration (Shin et al., 2012) and sporadic ALS (Melamed et al., 2019) , 133 declined with a similar timecourse ( Fig. 2A,B ). 134
We have recently reported that lowering the expression of NMNAT2 increases axonal 135 vulnerability to several stresses (Gilley et al., 2019) . To test whether lowering NMNAT2 136 expression impairs the ability to withstand mitochondrial impairment, SCG neurons 137 from mice with around 60% (Nmnat2 +/gtE ) and 30% (Nmnat2 gtBay/gtE ) of wild type 138
Nmnat2 mRNA levels in whole brain (Gilley et al., 2019) were exposed to CCCP. We 139 found a significant acceleration of the degeneration process compared to wild type 140 neurons, with clear morphological damage appearing as early as 4 hr in Nmnat2 gtBay/gtE 141 neurites ( Fig. 2D,E) . 142
These data suggest that mitochondrial uncoupling activates the Wallerian pathway at 143 an early step and, together with the protection afforded by WLD S (Fig. 1F ,G), they 144 indicate that axonal NMNAT levels modulate axon survival after mitochondrial 145 depolarisation. 146
NMNAT2 depletion reflects impairment of both axonal transport and synthesis 147
We next investigated the cause of NMNAT2 depletion after CCCP treatment. Being a 148 labile protein with a half-life of less than an hour (Milde et al., 2013) , any cellular 149 process that impairs its replenishment in axons would lead to a rapid decrease in 150 axonal levels. Two potential mechanisms are a deficiency in axonal transport and/or 151 altered synthesis, both of which are ATP-dependent. The finding that NMNAT2 levels 152 also declined in the cell body/ganglia fraction after 4-8 hr of CCCP addition (Fig. 3A,B ) 153
suggests that synthesis of the protein is impaired (although enhanced protein 154 degradation cannot be ruled out). However, the NMNAT2 decrease in the cell body 155 fraction was much less marked than that in neurites ( Fig. 2A,B ), suggesting that 156 impaired protein synthesis is not the only mechanism contributing to the depletion in 157 the neurites. SCG10 levels in the cell body fraction, instead, did not vary significantly 158 ( Fig. 3A,B ). 159
We next explored whether CCCP alters NMNAT2 axonal transport. We microinjected 160 GFP-tagged NMNAT2 and followed changes in its axonal transport parameters. We 161 found a significant reduction of the percentage of motile NMNAT2 vesicles at 4 and 8 162
hr after CCCP addition ( Fig. 3C ,D). This may also explain the slight recovery of 163 NMNAT2 levels in cell bodies at 8 hr after CCCP addition following the decline at 4 hr 164 ( Fig. 3A,B ), as any NMNAT2 that is synthesised would be less efficiently transported 165 into neurites and would accumulate in cell bodies instead. The overall reduction in 166 axonal transport of NMNAT2 appeared to be a result of a combination of impaired 167 anterograde, retrograde and bidirectional transport, although separately none of the 168 individual parameters reached statistical significance ( Fig. 3E ). 169
Thus, reduced axonal transport of NMNAT2 and reduced synthesis and/or enhanced 170 degradation combine to reduce axonal NMNAT2 levels after CCCP treatment. 171
Changes in the NMN/NAD ratio following CCCP administration 172
We have shown that NMNAT2 depletion leads to accumulation of its substrate, NMN, additional indicator of Wallerian pathway activation. We previously reported a marked 177 increase of NMN levels in injured sciatic nerves in vivo (Di Stefano et al., 2015 Stefano et al., , 2017 . 178
Sasaki and colleagues recently showed a transient increase in NMN levels in sensory 179 neurons after axotomy also in vitro (Sasaki et al., 2016) . However, selecting the correct 180 time points is difficult due to the substantial cellular material required for the analysis 181 and the rapid degeneration process which compromises the integrity of the plasma 182 membrane, making any measurement unreliable. We therefore tested whether NMN 183 accumulates and NAD declines following mitochondrial depolarisation in Sarm1 -/-SCG 184 neurons, where the degeneration process following CCCP administration is strongly 185 delayed ( Fig. 1D ,E). We looked at 12 hr after CCCP treatment, when wild-type neurites 186
showed the first signs of degeneration ( Fig. 2C,D) , reasoning that an increase in NMN 187 levels should have already occurred. We found a 2-fold increase in NMN levels and a 188 more modest decrease in NAD levels in neurites resulting in a robust increase in the 189 NMN/NAD ratio ( We therefore tested whether NMN accumulation also promotes axon degeneration 203 after CCCP administration. We first confirmed that the levels of NAMPT were not 204 affected by CCCP treatment (Fig. 5A,B ). This is important since NAMPT expression 205 is required for NMN synthesis, which results in the accumulation of NMN in the 206 absence of NMNAT2. We then tested whether blocking NMN synthesis with FK866 207 delays CCCP-induced axon degeneration. As with axon degeneration after axotomy 208 The Wallerian pathway is evolutionary conserved, with several orthologous genes 238 controlling axon degeneration both in mammals and flies (Freeman, 2014) ( Fig. S3 ). 239
As ubiquitous dSarm deletion is lethal in Drosophila, we instead opted to assess the 240 effects of Highwire mutation on the Pink1 B9 phenotype. Highwire, and its mammalian 241 ortholog PHR1, are E3 ubiquitin ligases that target Drosophila NMNAT (dNMNAT) and 242 NMNAT2, respectively, for proteasomal degradation and Highwire/PHR1 depletion 243 appears to delay axon degeneration after axotomy by increasing levels and/or 244 2014)). This indicates that WLD S expression and 278 SARM1 deficiency confer protection downstream of mitochondrial impairment (Fig. 7) , 279 rather than directly impacting on mitochondrial health. 280
The relevance of the Wallerian pathway beyond its role after axotomy is now widely 281 accepted and mitochondrial depolarisation can now be added to a growing list of non-282 axotomy insults causing Wallerian-like degeneration, including toxicity caused by 283 chemotherapy agents, chemicals disruption of the nigrostriatal pathway, protein 284 synthesis inhibition and NGF withdrawal (Conforti et al., 2014) . Importantly, most of 285 these studies used either WLD S expression or Sarm1 deletion as means to assess the 286 involvement of Wallerian-like degeneration. However, these proteins are likely to have 287 additional, non-Wallerian pathway functions and could thus confer a protective 288 phenotype independently of the Wallerian pathway. For example, WLD S protection 289 against neuropathy and retinopathy in a streptozotocin-induced mouse model of 290
diabetes is linked to a rescue of pancreatic islets (Zhu et al., 2011) , likely through a 291 mechanism that is unrelated to its role in axons. Recent steps forward in the 292 understanding of the molecular mechanisms of axon degeneration revealed a well-293 defined pathway of axon death, with the identification of crucial mechanistic links 294 between NMNAT2 and SARM1 (Gilley et al., 2015 (Gilley et al., , 2017 . The knowledge of a core 295 mechanistic pathway allows multiple stages to be probed when seeking to establish a 296 role for the Wallerian pathway in non-axotomy insults and diseases. Here, we followed 297 this approach focusing on NMNAT2 levels, changes in NMN/NAD ratio and protection 298 conferred by WLD S expression and Sarm1 deletion. This is the first demonstration of 299
Wallerian pathway involvement at multiple steps in a non-axotomy axonal stress. has one NMNAT isoform (compared to three in mammals) and so a reduction in 314 dNMNAT levels would likely cause a more profound damage to the whole cell, rather 315 than predominantly affecting axons (as it is the case with the major axonal isoform, 316 NMNAT2, in mammals). Finally, we cannot fully rule out the possibility that other 317 actions of Highwire contribute to these observations. 318
Among a number of neurodegenerative disorders associated with mitochondrial 319 dysfunction, the link between PD and axon loss is particularly important. PD involves 320 preferential loss of substantia nigra pars compacta dopaminergic neurons. These now be added to the list. However, more comprehensive studies in genetic and chronic 328 models of PD in mammals will be needed to establish whether the Wallerian pathway 329 plays a causative role in PD pathology or simply increases susceptibility to disease. 330
Interestingly, we also show that lower levels of NMNAT2 make neurites more 331 vulnerable to the consequences of CCCP-induced mitochondrial depolarisation and, 332 as NMNAT2 mRNA levels have been reported to vary hugely in the human population 333 (up to 50-fold differences) (Ali et al., 2016), some individuals might thus be at a much 334 higher risk of mitochondrial disorders. 335
To conclude, we show that acute mitochondrial impairment induced by CCCP leads 336 to NMNAT2 depletion and subsequent activation of the Wallerian pathway (Fig. 7) , 337
and that loss of dopaminergic neurons as a result of mitochondrial dysfunction in flies 338
with Pink1 loss-of-function mutation can be prevented by modulation of the Wallerian 339 pathway by Highwire deletion. This study provides mechanistic insights on how 340 mitochondrial dysfunction leads to axon degeneration and identifies the Wallerian 341 pathway as a potential contributor to axon pathology in mitochondrial disorders. It is 342 now important to test the role of the pathway in models that more closely replicate 343 human mitochondrial diseases. 344
MATERIALS AND METHODS 345
All studies conformed to the institution's ethical requirements in accordance with the 346 1986 Animals (Scientific Procedures) Act. 347
Primary neuronal cultures 348
C57BL/6J or CD1 (referred to as wild-type, Charles River, UK), Wld S , Nmnat2 +/+ , 349 Proteintech, 1:3000). Mouse anti β-actin was used as a loading control (A5316 Sigma, 404 1:5000). Quantification of band intensity was determined by densitometry using 405
ImageJ. 406
NMNAT2 axonal transport 407
Dissociated SCG neurons were microinjected using a Zeiss Axiovert S100 microscope 408 with an Eppendorf FemtoJet microinjector and Eppendorf TransferMan ® 409 micromanipulator. Plasmids were diluted in 0.5x PBS (without CaCl2 and MgCl2) and 410 filtered using a Spin-X filter (Costar). The mix was injected directly into the nuclei of 411 SCG neurons using Eppendorf Femtotips. Approximately 100 neurons were injected 412 per dish. Injected plasmids were allowed to express for 16 hr before CCCP treatment. 413
Plasmids were injected at the following concentrations: 30 ng/µl NMNAT2-EGFP, 30 414 ng/µl pDsRed2-N1. Time-lapse imaging of axonal transport was performed on an 415 Olympus IX70 imaging system with 100X/1.35 Oil objective. During imaging, cell 416 cultures were maintained at 37°C and 5% CO2 in an environment chamber. Images 417 were captured at 4 frames per sec for 2 min. Three neurites per condition were imaged 418 in every individual experiment. 419
Determination of NMN and NAD levels 420
Following treatment with CCCP, Sarm1 -/-SCG ganglia were separated from their 421 neurites with a scalpel. Neurites and cell bodies were washed in ice-cold PBS and 422 rapidly frozen in dry ice and stored at −80 °C until processed for measuring NMN and and Hiw DN Pink1 B9 . All flies were maintained at a constant 25°C temperature and 432 humidity, in plastic vials with standard agar/cornmeal/yeast feed. Flies were exposed 433 to a 12 hr light-dark cycle. All experiments were conducted on male flies. For PPL1 434 dopaminergic neuron staining, fly brains were dissected in cold 1x PBS and fixed in 435 4% paraformaldehyde-PBS (Sigma) for 30 min. Samples were washed in 1x PBS with 436 0.3% Triton X-100 (Sigma) and blocked for 1 hr at room temperature in 1x PBS with 437 0.3% Trition X-100 and 1% BSA (Sigma). Brains were incubated in primary antibody 438 for 72 hr. After washing and incubation in a fluorescent secondary antibody solution 439 for 4 hr, samples were mounted between two coverslips in ProLong diamond antifade 440 mountant (ThermoFisher). Confocal images were acquired on a Leica microscopy 441 system and blinded for analysis. Antibodies used were mouse anti-Tyrosine 442
Hydroxylase 1:100 (22941, Immunostar Inc.) and secondary anti-mouse IgG (H+L) 443
Alexa Fluor 488 (A11034, ThermoFisher). Flight assay was performed as previously 444 described (Agrawal and Hasan, 2015) . Briefly, flies were anaesthetised on ice for 5 445 min; the flat of a 30G 1" needle (Sigma) was attached to the anterior notum of a fly 446 just posterior to the neck using clear nail varnish, leaving flight muscles unimpeded. 447 was graded into 5 mm intervals, flies that climbed less than 5 cm were scored zero, 457 and any fly that exceeded 5 cm was awarded the maximum score. This was repeated 458 3 times at 60 sec intervals and an average score given for that vial. 459
Statistical analysis 460
Appropriate statistical testing of data was performed using Prism (GraphPad Software, 461 
